Gunilla Osswald

1.5k total citations · 1 hit paper
12 papers, 978 citations indexed

About

Gunilla Osswald is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Gunilla Osswald has authored 12 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 5 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Gunilla Osswald's work include Alzheimer's disease research and treatments (8 papers), Cholinesterase and Neurodegenerative Diseases (4 papers) and Prion Diseases and Protein Misfolding (3 papers). Gunilla Osswald is often cited by papers focused on Alzheimer's disease research and treatments (8 papers), Cholinesterase and Neurodegenerative Diseases (4 papers) and Prion Diseases and Protein Misfolding (3 papers). Gunilla Osswald collaborates with scholars based in Sweden, United States and Netherlands. Gunilla Osswald's co-authors include Lars Lannfelt, Christer Möller, Andrew Satlin, Linda Söderberg, Hanna Laudon, Veronika Logovinsky, Hans Basun, Patrik Nygren, Malin Johannesson and Fredrik Eriksson and has published in prestigious journals such as Scientific Reports, Journal of Neurochemistry and Drug Discovery Today.

In The Last Decade

Gunilla Osswald

11 papers receiving 944 citations

Hit Papers

Lecanemab, Aducanumab, and Gantenerumab — Binding Profile... 2022 2026 2023 2024 2022 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease
    2022 270 citations Linda Söderberg, Malin Johannesson et al. Neurotherapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gunilla Osswald Sweden 8 711 337 326 249 172 12 978
Hanna Laudon Sweden 14 777 1.1× 279 0.8× 425 1.3× 158 0.6× 137 0.8× 18 1000
Samantha Budd Haeberlein United States 13 784 1.1× 360 1.1× 271 0.8× 267 1.1× 174 1.0× 40 1.1k
Linda Söderberg Sweden 19 1.0k 1.4× 308 0.9× 548 1.7× 254 1.0× 309 1.8× 29 1.4k
Katherine R. Sadleir United States 12 850 1.2× 256 0.8× 488 1.5× 122 0.5× 255 1.5× 21 1.3k
Jasna Jerecı̀ć United States 11 673 0.9× 242 0.7× 406 1.2× 143 0.6× 162 0.9× 18 985
Boris Decourt United States 17 487 0.7× 183 0.5× 323 1.0× 89 0.4× 231 1.3× 48 1.0k
Annelies Vandersteen Belgium 7 1.1k 1.6× 285 0.8× 619 1.9× 258 1.0× 124 0.7× 8 1.3k
Audrey Gray United States 12 677 1.0× 216 0.6× 314 1.0× 118 0.5× 148 0.9× 20 944
Paul Acton United States 8 605 0.9× 177 0.5× 243 0.7× 116 0.5× 151 0.9× 9 753
Lisa M. Jungbauer United States 12 852 1.2× 173 0.5× 580 1.8× 120 0.5× 230 1.3× 18 1.3k

Countries citing papers authored by Gunilla Osswald

Since Specialization
Citations

This map shows the geographic impact of Gunilla Osswald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gunilla Osswald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gunilla Osswald more than expected).

Fields of papers citing papers by Gunilla Osswald

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gunilla Osswald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gunilla Osswald. The network helps show where Gunilla Osswald may publish in the future.

Co-authorship network of co-authors of Gunilla Osswald

This figure shows the co-authorship network connecting the top 25 collaborators of Gunilla Osswald. A scholar is included among the top collaborators of Gunilla Osswald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gunilla Osswald. Gunilla Osswald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Zachrisson, Olof, Malin Johannesson, Linda Söderberg, et al.. (2025). Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies. Neurotherapeutics. 23(1). e00779–e00779.
2.
Johannesson, Malin, Linda Söderberg, Olof Zachrisson, et al.. (2024). Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Molecular and Cellular Neuroscience. 130. 103949–103949. 20 indexed citations
3.
Zachrisson, Olof, Adeline Rachalski, Eleni Gkanatsiou, et al.. (2024). Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice. Molecular and Cellular Neuroscience. 130. 103950–103950. 2 indexed citations
4.
Söderberg, Linda, Malin Johannesson, Eleni Gkanatsiou, et al.. (2024). Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Scientific Reports. 14(1). 10868–10868. 22 indexed citations
5.
Xiong, Hao, Cindy Zadikoff, Qingbo Li, et al.. (2024). Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults. The Journal of Clinical Pharmacology. 64(11). 1432–1442. 2 indexed citations
6.
Söderberg, Linda, Malin Johannesson, Patrik Nygren, et al.. (2022). Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics. 20(1). 195–206. 270 indexed citations breakdown →
7.
Fälting, Johanna, et al.. (2020). How partnership should work to bring innovative medicines to patients. Drug Discovery Today. 25(6). 965–968. 4 indexed citations
8.
Logovinsky, Veronika, Andrew Satlin, Robert Lai, et al.. (2016). Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer s Research & Therapy. 8(1). 14–14. 212 indexed citations
9.
Lannfelt, Lars, Christer Möller, Hans Basun, et al.. (2014). Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimer s Research & Therapy. 6(2). 16–16. 118 indexed citations
10.
Tucker, Stina, Christer Möller, Karin Tegerstedt, et al.. (2014). The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice. Journal of Alzheimer s Disease. 43(2). 575–588. 200 indexed citations
11.
Georgievska, Biljana, Johan Sandin, James Doherty, et al.. (2013). AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. Journal of Neurochemistry. 125(3). 446–456. 98 indexed citations
12.
Stevens, Jasper, Bart A. Ploeger, Margareta Hammarlund‐Udenaes, et al.. (2012). Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. Journal of Pharmacokinetics and Pharmacodynamics. 39(5). 463–477. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hanna Laudon Breakdown of academic impact, for papers by Samantha Budd Haeberlein Breakdown of academic impact, for papers by Linda Söderberg Breakdown of academic impact, for papers by Katherine R. Sadleir Breakdown of academic impact, for papers by Jasna Jerecı̀ć Breakdown of academic impact, for papers by Boris Decourt Breakdown of academic impact, for papers by Annelies Vandersteen Breakdown of academic impact, for papers by Audrey Gray Breakdown of academic impact, for papers by Paul Acton Breakdown of academic impact, for papers by Lisa M. Jungbauer
Rankless by CCL
2026